2021
DOI: 10.48550/arxiv.2104.14923
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

A Comparison of Model-Free Phase I Dose Escalation Designs for Dual-Agent Combination Therapies

Helen Yvette Barnett,
Matthew George,
Donia Skanji
et al.

Abstract: It is increasingly common for therapies in oncology to be given in combination. In some cases, patients can benefit from the interaction between two drugs, although often at the risk of higher toxicity. A large number of designs to conduct phase I trials in this setting are available, where the objective is to select the maximum tolerated dose combination (MTC). Recently, a number of model-free (also called model-assisted) designs have provoked interest, providing several practical advantages over the more con… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

1
0

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 19 publications
(30 reference statements)
0
1
0
Order By: Relevance
“…As a result, a number of methods to identify the MTC have been proposed in the literature in the last two decades. [3][4][5] Despite a number of available alternatives and the fact that more efficient statistical methods in Phase I clinical trials can noticeably increase the probability of the success by the end of Phase III studies, 1 their uptake in clinical practice remains low. 6 Another emerging field in early phase drug development is dose-schedule clinical trials in which the safety and tolerability of a monotherapy administered using various schedules is studied.…”
Section: Introductionmentioning
confidence: 99%
“…As a result, a number of methods to identify the MTC have been proposed in the literature in the last two decades. [3][4][5] Despite a number of available alternatives and the fact that more efficient statistical methods in Phase I clinical trials can noticeably increase the probability of the success by the end of Phase III studies, 1 their uptake in clinical practice remains low. 6 Another emerging field in early phase drug development is dose-schedule clinical trials in which the safety and tolerability of a monotherapy administered using various schedules is studied.…”
Section: Introductionmentioning
confidence: 99%